Health Care [ 9/12 ] | Pharmaceuticals [ 61/74 ]
NASDAQ | Common Stock
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.
The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation.
Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -1.22 Increased by +15.58% | -1.21 Decreased by -0.47% |
| Feb 18, 25 | -1.54 Increased by +25.96% | -1.00 Decreased by -53.60% |
| Nov 12, 24 | -1.34 Decreased by -1.66% | -1.41 Increased by +4.83% |
| Aug 5, 24 | -1.67 Decreased by -8.44% | -1.33 Decreased by -25.56% |
| May 6, 24 | -1.44 Decreased by -453.85% | -1.20 Decreased by -20.00% |
| Feb 20, 24 | -2.08 Decreased by -47.52% | -1.17 Decreased by -77.78% |
| Nov 6, 23 | -1.32 Decreased by -23.36% | -1.20 Decreased by -10.00% |
| Aug 7, 23 | -1.54 Decreased by -45.28% | -1.22 Decreased by -26.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 121.46 M Increased by +61.95% | -59.41 M Increased by +13.08% | Decreased by -48.91% Increased by +46.33% |
| Dec 31, 24 | 118.77 M Increased by +66.04% | -74.91 M Increased by +24.06% | Decreased by -63.08% Increased by +54.27% |
| Sep 30, 24 | 104.76 M Increased by +81.27% | -64.60 M Decreased by -3.86% | Decreased by -61.67% Increased by +42.70% |
| Jun 30, 24 | 87.17 M Increased by +86.65% | -79.34 M Decreased by -18.13% | Decreased by -91.03% Increased by +36.71% |
| Mar 31, 24 | 75.00 M Decreased by -20.70% | -68.36 M Decreased by -509.35% | Decreased by -91.14% Decreased by -668.41% |
| Dec 31, 23 | 71.53 M Increased by +193.50% | -98.65 M Decreased by -47.76% | Decreased by -137.92% Increased by +49.65% |
| Sep 30, 23 | 57.79 M Increased by +243.08% | -62.20 M Decreased by -31.68% | Decreased by -107.62% Increased by +61.62% |
| Jun 30, 23 | 46.70 M Increased by +429.49% | -67.17 M Decreased by -56.81% | Decreased by -143.83% Increased by +70.39% |